Essay. How to interpret the evidence

Summary

Iron availability shapes competition among gut microbes. When dietary or supplemental iron exceeds absorption in the small intestine, the unabsorbed fraction reaches the colon. Trials in Kenyan infants and Ivorian children show that iron fortification can increase enterobacteria and intestinal inflammation.[1][2] Reviews connect these findings with mechanisms of bacterial iron acquisition, but clinical outcomes vary across settings.[3][4] A larger Bangladeshi trial found no increase in diarrhea and no microbiome change in its primary analysis.[5] The evidence supports a context-dependent pathway linking iron exposure, microbial ecology, and disease risk; it does not establish that every iron intervention increases enteric infection.

Key takeaways

  • In infant food-fortification settings, more than 80% of an oral iron dose may remain unabsorbed and reach the colon.[1][3]
  • Trials in Kenyan infants and Ivorian children found increases in enterobacteria and other potentially harmful taxa; some trials also found decreases in Bifidobacterium or Lactobacillus.[1][2][6]
  • In Kenyan infants, iron increased pathogenic E. coli from about 4.5 to 6.0 log gene copies/g stool. Fecal calprotectin was significantly higher with the 12.5 mg formulation.[1]
  • In the Kenyan high-dose comparison, diarrhea treatment was more frequent with iron (27.3% versus 8.3%), but the difference was not statistically significant (p = 0.092).[1] A review reported a small pooled increase in diarrhea risk with micronutrient powders, while the larger Bangladeshi trial found no increase.[4][5]
  • Salmonella can evade host lipocalin-2 through the siderophore salmochelin. In mouse experiments, probiotic E. coli Nissle reduced Salmonella colonization only when its iron-uptake systems were functional.[7][8]
  • Iron overload increases susceptibility to siderophilic infections. Experiments with Vibrio vulnificus and Yersinia demonstrate how impaired iron restriction can worsen infection.[9][10]

The exposure: most oral iron never gets absorbed

Iron absorption is regulated according to iron needs and inflammation, with the hormone hepcidin limiting uptake when it is elevated. For a typical in-home fortification dose given to weaning infants, more than 80% of the iron can pass unabsorbed into the large intestine, where the dense resident microbiota lives.[1][3][4] Iron fortification can therefore create substantial colonic exposure even when only a small fraction of the dose is absorbed.

This matters because host iron restriction helps limit microbial growth. Some beneficial gut bacteria, including lactobacilli, have low iron requirements, whereas many enteric pathogens depend on iron for growth and virulence.[2][3] Poorly absorbed iron can change that competitive environment. Relevant exposures include iron-containing micronutrient powders, fortified complementary foods, oral iron supplements, and fortified staples. Systemic iron overload also alters susceptibility to infection, through a different exposure pathway.[4][9]

The microbiome change: named winners and losers

Several African trials found an increase in enterobacteria, including Escherichia coli and Escherichia/Shigella taxa, after iron fortification. Other reported changes included increased Clostridium or Clostridiales and reduced Bifidobacterium or Lactobacillus, depending on the study and formulation.[1][2][6] In the Kenyan infant trial, the enterobacteria-to-bifidobacteria ratio increased, indicating a shift in the balance of the community.[1]

The numbers from the Kenyan infant trial are concrete. In 6-month-old infants randomized to iron-containing micronutrient powders, abundances of pathogenic E. coli reached roughly 6.0 log gene copies per gram of stool versus about 4.5 in the no-iron control group.[1] The Cote d'Ivoire trial in older children found a significant increase in fecal enterobacteria and a significant decrease in lactobacilli after six months of iron-fortified biscuits.[2] Pathogen carriage was common in the Kenyan study, including pathogenic E. coli and Salmonella.[1] A larger trial in 923 Bangladeshi infants found no increase in diarrhea and no change in microbiome diversity or composition in its primary analysis; shifts toward some potential pathogens appeared in exploratory analyses without adjustment for multiple comparisons.[5]

Changes in microbial composition are more informative when assessed alongside host outcomes. In both the Kenyan and Ivorian trials, iron increased fecal calprotectin, a marker of intestinal inflammation, with associations between calprotectin and enterobacteria.[1][2] In the Kenyan study, calprotectin was significantly higher with the 12.5 mg iron formulation but not the 2.5 mg formulation. Because the formulations also differed, this comparison does not isolate dose as the explanation.[1]

Clinical diarrhea outcomes were less consistent. In the Kenyan high-dose comparison, 27.3% of infants receiving iron required diarrhea treatment versus 8.3% of controls, but the difference was not statistically significant (p = 0.092).[1] A review reported a small pooled increase in diarrhea with micronutrient powders (relative risk 1.04; 95% CI 1.01 to 1.06), as well as bloody diarrhea in a Pakistani trial and increased hospital admissions during a Ghanaian intervention.[4] In contrast, the larger Bangladeshi trial found no increase in diarrhea.[5] Benefits also differed: fortification did not improve iron status or anemia in the Ivorian trial, whereas the higher-dose Kenyan formulation improved iron-status measures.[1][2]

The mechanism: iron as a pathogen's growth factor and weapon

One mechanism involves nutritional immunity, the host strategy of restricting microbes' access to essential metals. Many enteric pathogens use high-affinity iron chelators called siderophores to acquire iron. The host protein lipocalin-2 binds the siderophore enterobactin and restricts its use, creating pressure for bacterial iron-acquisition systems that evade this defense.[7]

Salmonella Typhimurium produces salmochelin, a modified siderophore that evades lipocalin-2. Experiments showed that resistance to lipocalin-2 gives Salmonella a competitive advantage in the inflamed intestine.[7] In mouse models, probiotic E. coli Nissle 1917 reduced Salmonella colonization by competing for iron; mutants with impaired iron uptake lost this protective effect.[8] These experiments establish that iron acquisition can influence intestinal competition. Whether additional dietary iron produces clinical harm depends on the organisms, host, and exposure conditions.

Iron overload and siderophilic infections

Systemic iron excess increases vulnerability to iron-loving, or siderophilic, pathogens. Hereditary hemochromatosis, associated with inadequate hepcidin signaling and iron accumulation, is a recognized risk setting for severe infections with organisms such as Vibrio vulnificus and Yersinia. Experimental models help explain how available iron changes their pathogenicity.[9][10]

Hepcidin-deficient mice were more susceptible to Vibrio vulnificus, and their iron-rich serum supported rapid bacterial growth. Hepcidin agonists lowered circulating iron and improved survival in these experiments.[9] In another study, a hyperyersiniabactin-producing Yersinia pseudotuberculosis mutant caused acute lethal disease in iron-overloaded mice, with excessive IL-1-beta signaling and disruption of the intestinal barrier.[10] These models demonstrate mechanisms linking iron availability to infection severity under iron-overload conditions.

Weighing human against animal and mechanistic evidence

Randomized trials provide direct evidence that iron can alter the microbiome and increase intestinal inflammation in some settings.[1][2] Clinical outcomes are less consistent: the Kenyan diarrhea-treatment difference was not statistically significant, and the larger Bangladeshi trial found no increase in diarrhea.[1][5] These differences make population, baseline iron status, formulation, and outcome definitions central to interpreting the evidence.

Mechanistic and animal studies show how siderophores, lipocalin-2, and competing bacteria influence iron acquisition, and how iron overload can worsen particular infections.[7][8][9][10] Together with the human trials, they support a plausible pathway through which iron availability affects microbial ecology and host health. Demonstrating that a microbiome change mediates a clinical infection outcome requires further evidence.

Limitations and what would confirm it

The populations and formulations studied differ, and effects should not be assumed to generalize to every setting. The Bangladeshi trial's primary null result illustrates this uncertainty.[5] Formulation is also relevant: a Kenyan trial combining low-dose, bioavailable iron with prebiotic galacto-oligosaccharides reduced anemia while mitigating several adverse microbiome and intestinal effects.[6] Diarrhea has many causes, and a change in microbial abundance alone does not establish an increase in clinical infection.

Further studies could compare formulations and doses while measuring colonic iron, microbial strains, inflammation, and clinical infections together. Strain-resolved metagenomics could identify which iron-acquisition systems matter, while mediation analyses could test whether microbial changes account for clinical outcomes. The current evidence supports considering colonic exposure when evaluating iron interventions and assessing both their hematologic benefits and their gastrointestinal effects.

Cite this page

Karen Pendergrass. (2026-07-14). Feeding the Enemy: How Dietary Iron Reshapes the Gut Microbiome and Raises Enteric Infection Risk. Microbial Metallomics. https://microbialmetallomics.com/blog/dietary-iron-microbiome-enteric-infection

This citation identifies this website page.

Published at https://microbialmetallomics.com/blog/dietary-iron-microbiome-enteric-infection

Related concepts

Nutritional immunitySiderophoreCalprotectinIronZinc

Frequently asked questions

Does taking iron supplements increase your risk of gut infection?

Iron fortification can increase enterobacteria and intestinal inflammation in some infant and child populations. Diarrhea outcomes vary: the Kenyan high-dose comparison was not statistically significant, and a larger Bangladeshi trial found no increase. Effects depend on the population and formulation.[1][2][5]

Why does unabsorbed iron favor harmful bacteria over beneficial ones?

Many enteric pathogens need iron and use siderophores to acquire it. Host lipocalin-2 restricts enterobactin, while Salmonella can evade this defense using salmochelin. Differences in iron acquisition can therefore alter competition among microbes.[7][8]

What is the human evidence, not just animal studies?

Randomized trials in Kenyan infants and Ivorian children documented microbiome changes and increased fecal calprotectin. The larger Bangladeshi trial found no microbiome change in its primary analysis and no increase in diarrhea. Human evidence supports effects in some settings, with uncertainty about how microbial changes translate into clinical infection.[1][2][5]

Is there a way to give iron without harming the gut?

One Kenyan trial found that low-dose, bioavailable iron reduced anemia and that adding prebiotic galacto-oligosaccharides mitigated several adverse microbiome and intestinal effects. Formulation and co-interventions may therefore influence the balance of benefits and harms, but that result does not establish safety for every population.[6]

What is iron overload and how does it relate to siderophilic infections?

Iron overload is excessive iron accumulation in the body. In hereditary hemochromatosis, inadequate hepcidin signaling contributes to this accumulation and susceptibility to some siderophilic infections. Mouse experiments with Vibrio vulnificus and Yersinia show how impaired iron restriction can worsen infection; these models differ from routine dietary supplementation.[9][10]

References

  1. Jaeggi T, Kortman GAM, Moretti D, et al. (2015). Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. View source↩1↩2↩3↩4↩5↩6↩7↩8↩9↩10↩11↩12↩13↩14↩15↩16↩17↩18
  2. Zimmermann MB, Chassard C, Rohner F, et al. (2010). The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d'Ivoire. American Journal of Clinical Nutrition. View source↩1↩2↩3↩4↩5↩6↩7↩8↩9↩10
  3. Paganini D, Zimmermann MB (2017). The effects of iron fortification and supplementation on the gut microbiome and diarrhea in infants and children: a review. American Journal of Clinical Nutrition. View source↩1↩2↩3↩4
  4. Paganini D, Uyoga MA, Zimmermann MB (2016). Iron Fortification of Foods for Infants and Children in Low-Income Countries: Effects on the Gut Microbiome, Gut Inflammation, and Diarrhea. Nutrients. View source↩1↩2↩3↩4↩5
  5. Baldi A, Braat S, Hasan MI, et al. (2024). Effects of iron supplements and iron-containing micronutrient powders on the gut microbiome in Bangladeshi infants: a randomized controlled trial. Nature Communications. View source↩1↩2↩3↩4↩5↩6↩7↩8
  6. Paganini D, Uyoga MA, Kortman GAM, et al. (2017). Prebiotic galacto-oligosaccharides mitigate the adverse effects of iron fortification on the gut microbiome: a randomised controlled study in Kenyan infants. Gut. View source↩1↩2↩3↩4
  7. Raffatellu M, George MD, Akiyama Y, et al. (2009). Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell Host & Microbe. View source↩1↩2↩3↩4↩5
  8. Deriu E, Liu JZ, Pezeshki M, et al. (2013). Probiotic bacteria reduce Salmonella Typhimurium intestinal colonization by competing for iron. Cell Host & Microbe. View source↩1↩2↩3↩4
  9. Arezes J, Jung G, Gabayan V, et al. (2015). Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus. Cell Host & Microbe. View source↩1↩2↩3↩4↩5↩6
  10. Das S, Saqib M, Meng RC, et al. (2022). Hemochromatosis drives acute lethal intestinal responses to hyperyersiniabactin-producing Yersinia pseudotuberculosis. PNAS. View source↩1↩2↩3↩4↩5

Keep reading

BlogThe metal–microbiome–disease axisBlogAll posts